DTRMWXHS-12 is under clinical development by Zhejiang DTRM Biopharma and currently in Phase I for B-Cell Non-Hodgkin Lymphoma. According to GlobalData, Phase I drugs for B-Cell Non-Hodgkin Lymphoma have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DTRMWXHS-12’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

DTRMWXHS-12 overview

DTRMWXHS-12 is under development for the treatment of B-cell lymphoma including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia with 17p, mantle cell lymphoma, marginal zone lymphoma (MZL), follicular B-cell non-Hodgkin's lymphoma (FL). The drug candidate is administered through oral route as a capsule. It acts by targeting Bruton's tyrosine kinase (BTK). It was also under development for the treatment of Waldenstrom's macroglobulinemia and diffuse large B-cell lymphoma.

Zhejiang DTRM Biopharma overview

Zhejiang DTRM Biopharma, a biotechnology company that manufactures pharmaceutical products. The company is headquartered in United States.

For a complete picture of DTRMWXHS-12’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.